Study Results Validate Use of Tumor Markers to Treat Metastatic Cancer
By LabMedica International staff writers Posted on 17 Jun 2019 |
A new study validated the use of tumor markers to select chemotherapy drugs for patients with metastatic pancreatic cancer (Photo courtesy of SPL).
Promising results obtained in a recently conducted pilot study demonstrated the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer.
Investigators at Georgetown University (Washington, DC, USA) and collaborators at several other institutions carried out a study designed to assess the feasibility of following a treatment algorithm based on the expression of three published predictive markers of response to chemotherapy: ribonucleotide reductase catalytic subunit M1 (for gemcitabine); excision repair cross-complementation group 1 (for platinum agents); and thymidylate synthase (for 5-fluorouracil) in patients with untreated, metastatic pancreatic cancer.
Initially, 30 patients were enrolled in the study. However, 10 patients failed screening primarily due to inadequate tumor tissue availability. Of the remaining 20 patients, tumor biopsy analysis was used to assign them to one of seven doublet treatment regimens. Key secondary objectives included response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Results revealed promising indications for progression-free survival and overall survival, with a partial response seen in 28% of patients and stable disease in 50% by completion of the study.
Based on the results from this pilot study, a larger phase II randomized trial of molecularly targeted therapy versus physicians' choice of standard of care has been initiated.
Results of the pilot study were discussed in the May 2, 2019, online edition of the Journal of Pancreatic Cancer.
Related Links:
Georgetown University
Investigators at Georgetown University (Washington, DC, USA) and collaborators at several other institutions carried out a study designed to assess the feasibility of following a treatment algorithm based on the expression of three published predictive markers of response to chemotherapy: ribonucleotide reductase catalytic subunit M1 (for gemcitabine); excision repair cross-complementation group 1 (for platinum agents); and thymidylate synthase (for 5-fluorouracil) in patients with untreated, metastatic pancreatic cancer.
Initially, 30 patients were enrolled in the study. However, 10 patients failed screening primarily due to inadequate tumor tissue availability. Of the remaining 20 patients, tumor biopsy analysis was used to assign them to one of seven doublet treatment regimens. Key secondary objectives included response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Results revealed promising indications for progression-free survival and overall survival, with a partial response seen in 28% of patients and stable disease in 50% by completion of the study.
Based on the results from this pilot study, a larger phase II randomized trial of molecularly targeted therapy versus physicians' choice of standard of care has been initiated.
Results of the pilot study were discussed in the May 2, 2019, online edition of the Journal of Pancreatic Cancer.
Related Links:
Georgetown University
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection